Journal for ImmunoTherapy of Cancer: 12 (4)

Basic tumor immunology

Original research: Germline homozygosity and allelic imbalance of HLA-I are common in esophagogastric adenocarcinoma and impair the repertoire of immunogenic peptides (17 April, 2024)
Maria Alejandra Garcia-Marquez, Martin Thelen, Eugen Bauer, Lukas Maas, Kerstin Wennhold, Jonas Lehmann, Diandra Keller, Miloš Nikolić, Julie George, Thomas Zander, Wolfgang Schröder, Philipp Müller, Ali M Yazbeck, Christiane Bruns, Roman Thomas, Birgit Gathof, Alexander Quaas, Martin Peifer, Axel M Hillmer, Michael von Bergwelt-Baildon, Hans Anton Schlößer
Original research: Dual molecule targeting HDAC6 leads to intratumoral CD4+ cytotoxic lymphocytes recruitment through MHC-II upregulation on lung cancer cells (11 April, 2024)
Sarah Ducellier, Mélanie Demeules, Boris Letribot, Massimiliano Gaetani, Chloé Michaudel, Harry Sokol, Abdallah Hamze, Mouad Alami, Mégane Nascimento, Sébastien Apcher
Original research: Tetracyclines enhance antitumor T-cell immunity via the Zap70 signaling pathway (15 April, 2024)
Mari Tone, Kota Iwahori, Michinari Hirata, Azumi Ueyama, Akiyoshi Tani, Jun-Ichi Haruta, Yoshito Takeda, Yasushi Shintani, Atsushi Kumanogoh, Hisashi Wada
Original research: Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses (8 April, 2024)
Bo Wang, Bingkun Zhou, Junyu Chen, Xi Sun, Wenjuan Yang, Tenghao Yang, Hao Yu, Peng Chen, Ke Chen, Xiaodong Huang, Xinxiang Fan, Wang He, Jian Huang, Tianxin Lin
Original research: Blocking senescence and tolerogenic function of dendritic cells induced by γδ Treg cells enhances tumor-specific immunity for cancer immunotherapy (5 April, 2024)
Fusheng Si, Xia Liu, Yan Tao, Yuanqin Zhang, Feiya Ma, Eddy C Hsueh, Sidharth V Puram, Guangyong Peng
Original research: Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer (5 April, 2024)
Antons Martincuks, Chunyan Zhang, Theresa Austria, Yi-Jia Li, Rui Huang, Nicole Lugo Santiago, Adrian Kohut, Qianqian Zhao, Rosemarie Martinez Borrero, Binghui Shen, Mihaela Cristea, Edward W Wang, Mihae Song, Lorna Rodriguez-Rodriguez, Hua Yu
Original research: Pyroptosis activates conventional type I dendritic cells to mediate the priming of highly functional anticancer T cells (4 April, 2024)
Jordon M Inkol, Michael J Westerveld, Shayla G Verburg, Scott R Walsh, Jodi Morrison, Karen L Mossman, Sarah M Worfolk, Kaslyn LF Kallio, Noah J Phippen, Rebecca Burchett, Yonghong Wan, Jonathan Bramson, Samuel T Workenhe

Case report

Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination (24 April, 2024)
Robert A Watson, Weiyu Ye, Chelsea A Taylor, Elsita Jungkurth, Rosalin Cooper, Orion Tong, Tim James, Brian Shine, Monika Hofer, Damian Jenkins, Robert Pell, Eleni Ieremia, Stephanie Jones, David Maldonado-Perez, Ian S D Roberts, Nicholas Coupe, Mark R Middleton, Miranda J Payne, Benjamin P Fairfax

Commentary

Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy (16 April, 2024)
Bao-Dong Qin, Xiao-Dong Jiao, Ling-Yan Yuan, Ying Wu, Yan Ling, Yuan-Sheng Zang
Do galectins serve as soluble ligands for immune checkpoint receptors? (9 April, 2024)
Nicolas I Torres, Federico G Baudou, Marco A Scheidegger, Tomás Dalotto-Moreno, Gabriel A Rabinovich
Targeting of netrin-1 by monoclonal antibody NP137 inhibits the EMT in cancer (4 April, 2024)
Xueli Xia, Kai Yin, Shengjun Wang

Clinical/translational cancer immunotherapy

Original research:
Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using ⁹⁰Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors
(24 April, 2024)
Anusha Muralidhar, Reinier Hernandez, Zachary S Morris, Hansel Comas Rojas, Malick Bio Idrissou, Jamey P Weichert, Douglas G McNeel
Original research: Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors (19 April, 2024)
Sophia Frentzas, Anna Rachelle Austria Mislang, Charlotte Lemech, Adnan Nagrial, Craig Underhill, Wenjing Wang, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jermaine I G Coward
Original research: Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma (17 April, 2024)
Florian Hornsteiner, Janine Vierthaler, Helen Strandt, Antonia Resag, Zhe Fu, Markus Ausserhofer, Christoph H Tripp, Sophie Dieckmann, Markus Kanduth, Kathryn Farrand, Sarah Bregar, Niloofar Nemati, Natascha Hermann-Kleiter, Athanasios Seretis, Sudhir Morla, David Mullins, Francesca Finotello, Zlatko Trajanoski, Guido Wollmann, Franca Ronchese, Marc Schmitz, Ian F Hermans, Patrizia Stoitzner
Original research: Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment (17 April, 2024)
Josipa Raguz, Catarina Pinto, Theresa Pölzlbauer, Mohamed Habbeddine, Sandra Rosskopf, Judith Strauß, Valentin Just, Sarah Schmidt, Katell Bidet Huang, Felix Stemeseder, Timo Schippers, Ethan Stewart, Jakub Jez, Pedro Berraondo, Klaus K. Orlinger, Henning Lauterbach
Original research: Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma (16 April, 2024)
Wei Liu, Wei Liu, Hesong Zou, Lianting Chen, Wenyang Huang, Rui Lv, Yan Xu, Huimin Liu, Yin Shi, Kefei Wang, Yi Wang, Wenjie Xiong, Shuhui Deng, Shuhua Yi, Weiwei Sui, Guangxin Peng, Yueshen Ma, Huijun Wang, Lulu Lv, Jianxiang Wang, Jun Wei, Lugui Qiu, Wenting Zheng, Dehui Zou
Original research: Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C (16 April, 2024)
Celia Gomar, Claudia Augusta Di Trani, Angela Bella, Leire Arrizabalaga, Jose Gonzalez-Gomariz, Myriam Fernandez-Sendin, Maite Alvarez, Joan Salvador Russo-Cabrera, Nuria Ardaiz, Fernando Aranda, Timo Schippers, Marisol Quintero, Ignacio Melero, Klaus K Orlinger, Henning Lauterbach, Pedro Berraondo
Original research: Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma (12 April, 2024)
David G Coffey, Keren Osman, Adolfo Aleman, Selma Bekri, Simone Kats, Amishi Dhadwal, Donna Catamero, Seunghee Kim-Schulze, Sacha Gnjatic, Ajai Chari, Samir Parekh, Sundar Jagannath, Hearn Jay Cho
Original research: Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC (11 April, 2024)
Nikolaus John, Verena Schlintl, Teresa Sassmann, Jörg Lindenmann, Melanie Fediuk, Robert Wurm, Philipp Douschan, Martin Zacharias, Lipika Kalson, Florian Posch, Gudrun Absenger, Luka Brcic, Philipp J Jost, Angelika Terbuch
Original research: Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A) (11 April, 2024)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet A Bilen, Mark Stein, Jeffrey Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael Hurwitz, David J Peace, David Einstein, Paul J Catalano, Hans Hammers, Meredith M Regan
Original research: Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics (11 April, 2024)
Yee Peng Phoon, Jared E Lopes, Lukas W Pfannenstiel, Claudia Marcela Diaz-Montero, Ye F Tian, Marc S Ernstoff, Pauline Funchain, Jennifer S Ko, Raymond Winquist, Heather C Losey, Jan Joseph Melenhorst, Brian R Gastman
Original research: Respiratory complex I regulates dendritic cell maturation in explant model of human tumor immune microenvironment (11 April, 2024)
Rita Turpin, Ruixian Liu, Pauliina M Munne, Aino Peura, Jenna H Rannikko, Gino Philips, Bram Boeckx, Natasha Salmelin, Elina Hurskainen, Ilida Suleymanova, July Aung, Elisa M Vuorinen, Laura Lehtinen, Minna Mutka, Panu E Kovanen, Laura Niinikoski, Tuomo J Meretoja, Johanna Mattson, Satu Mustjoki, Päivi Saavalainen, Andrei Goga, Diether Lambrechts, Jeroen Pouwels, Maija Hollmén, Juha Klefström
Original research: Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis (4 April, 2024)
Cathrin L C Gudd, Eoin Mitchell, Stephen R Atkinson, Marie-Anne Mawhin, Samra Turajlic, James Larkin, Mark R Thursz, Robert D Goldin, Nick Powell, Charalambos G Antoniades, Kevin J Woollard, Lucia A Possamai, Evangelos Triantafyllou

Immunotherapy biomarkers

Original research: Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma (27 April, 2024)
Judith M Versluis, Stephanie A Blankenstein, Petros Dimitriadis, James S Wilmott, Robert Elens, Willeke A M Blokx, Winan van Houdt, Alexander Maxwell Menzies, Yvonne M Schrage, Michel W J M Wouters, Joyce Sanders, Annegien Broeks, Richard A Scolyer, Karijn P M Suijkerbuijk, Georgina V Long, Alexander C J van Akkooi, Christian U Blank
Original research: Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials (22 April, 2024)
Andreas Roller, Iakov I Davydov, Petra C Schwalie, Martha L Serrano-Serrano, Astrid Heller, Nicolas Staedler, Cláudia S Ferreira, Gabriele Dietmann, Irina Klaman, Alberto Valdeolivas, Konstanty Korski, Michael A Cannarile
Original research:
Total metabolic tumor volume on ¹⁸F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy
(22 April, 2024)
Pierre Tricarico, David Chardin, Nicolas Martin, Sara Contu, Florent Hugonnet, Josiane Otto, Olivier Humbert
Original research:
Dysregulation of CD4⁺ and CD8⁺ resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis
(19 April, 2024)
Jun Yan He, Yang-Joon Kim, Elvira Mennillo, Iulia Rusu, Jared Bain, Arjun A Rao, Christopher Andersen, Karen Law, Hai Yang, Jessica Tsui, Alan Shen, Brittany Davidson, Divyashree Kushnoor, Yimin Shi, Frances Fan, Alexander Cheung, Li Zhang, Lawrence Fong, Alexis J Combes, Angela O Pisco, Michael G Kattah, David Y Oh
Original research: Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer (18 April, 2024)
Liang Zheng, Fang Hu, Lin Huang, Jun Lu, Xiaohua Yang, Jianlin Xu, Shuyuan Wang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Wei Zhang, Ying Li, Xiaoxuan Zheng, Baohui Han, Hua Zhong, Wei Nie, Xueyan Zhang
Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer (16 April, 2024)
Khyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy, Joshua J Meeks
Original research: OMA1 competitively binds to HSPA9 to promote mitophagy and activate the cGAS–STING pathway to mediate GBM immune escape (11 April, 2024)
Wen de Zhu, Jin Rao, Li hua Zhang, Ka ming Xue, Lin Li, Jun jun Li, Qian zhi Chen, Rong Fu
Original research: Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors (11 April, 2024)
Jared M Odegard, Ahmed A Othman, Kai-Wen Lin, Adele Y Wang, Jonathan Nazareno, Oh Kyu Yoon, John Ling, Latesh Lad, P Rod Dunbar, Dung Thai, Edmond Ang, Nicholas Waldron, Sanjeev Deva
Original research:
Preclinical development of novel PD-L1 tracers and first-in-human study of [⁶⁸Ga]Ga-NOTA-RW102 in patients with lung cancers
(5 April, 2024)
You Zhang, Min Cao, Yanfei Wu, Sara Malih, Dong Xu, Erpeng Yang, Muhsin H Younis, Wilson Lin, Haitao Zhao, Cheng Wang, Qiufang Liu, Jonathan W Engle, Mohammad J Rasaee, Yihui Guan, Gang Huang, Jianjun Liu, Weibo Cai, Fang Xie, Weijun Wei

Immune cell therapies and immune cell engineering

Original research: ScRNA-seq reveals novel immune-suppressive T cells and investigates CMV-TCR-T cells cytotoxicity against GBM (30 April, 2024)
Xinmiao Long, Zuping Zhang, Yuzhe Li, Kun Deng, Wei Gao, Meng Huang, Xiangyu Wang, Xiang Lin, Xiaoling She, Yiming Zhao, Minfu Zhang, Cheng Huang, Shiyi Wang, Yinfei Du, Peng Du, Shuai Chen, Qing Liu, Minghua Wu
Original research: Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T (29 April, 2024)
Natalia Ruggeri Barbaro, Theodore Drashansky, Kristina Tess, Mansour Djedaini, Robert Hariri, Shuyang He, William van der Touw, Kathy Karasiewicz
Original research: Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system (27 April, 2024)
Asmita Khaniya, S M Ali Hossieni Rad, Josh Halpin, Supannikar Tawinwung, Alexander McLellan, Koramit Suppipat, Nattiya Hirankarn
Original research: Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models (24 April, 2024)
Takuya Tada, Thomas D Norton, Rebecca Leibowitz, Nathaniel R Landau
Original research: Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer (16 April, 2024)
Aryana M Razmara, Lauren E Farley, Rayna M Harris, Sean J Judge, Marshall Lammers, Khurshid R Iranpur, Eric G Johnson, Cordelia Dunai, William J Murphy, C Titus Brown, Robert B Rebhun, Michael S Kent, Robert J Canter
Original research: Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1 (12 April, 2024)
Tri Minh Tran, Bal Krishna Chand Thakuri, Saule Nurmukhambetova, Jia-Jye Lee, Peirong Hu, Ngoc Q Tran, Brittany Steimle, Pradyot Dash, Dina Schneider
Original research: Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16 (11 April, 2024)
Nicholas P Casey, Katrin Kleinmanns, Christopher Forcados, Pascal F Gelebart, Sandy Joaquina, Martine Lode, Emmanuelle Benard, Fatemeh Kaveh, Benjamin Caulier, Christiane Helgestad Gjerde, Elvira García de Jalón, David J Warren, Kristina Lindemann, Erik Rokkones, Ben Davidson, Marit Renee Myhre, Gunnar Kvalheim, Line Bjørge, Emmet McCormack, Else Marit Inderberg, Sébastien Wälchli
Original research: PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion (8 April, 2024)
Wanyan Ouyang, Shi-Wei Jin, Nan Xu, Wei-Yang Liu, Han Zhao, Liuqingqing Zhang, Liqing Kang, Yi Tao, Yuanfang Liu, Yan Wang, Jin Wang, Feng Liu, Lei Yu, Zhiqiang Liu, Jian-Qing Mi
Original research: Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML (5 April, 2024)
Vania Lo Presti, Angelo Meringa, Ester Dunnebach, Alice van Velzen, Aida Valera Moreira, Ronald W Stam, Rishi S Kotecha, Anja Krippner-Heidenreich, Olaf T Heidenreich, Maud Plantinga, Annelisa Cornel, Zsolt Sebestyen, Jurgen Kuball, Niek P van Til, S Nierkens

Letter

Response to: Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Noguchi et al
(22 April, 2024)
Ahmed Sayed, Malak Munir, Michael Poliner, Sana Sughra, Narendranath Epperla, Daniel Addison
Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Sayed et al
(22 April, 2024)
Yoshihiro Noguchi, Miao Yan, Tomoya Tachi, Tomoaki Yoshimura

Oncolytic and local immunotherapy

Original research: Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade (24 April, 2024)
Jason K Cullen, Pei-Yi Yap, Blake Ferguson, Zara C Bruce, Motoko Koyama, Herlina Handoko, Kevin Hendrawan, Jacinta L Simmons, Kelly M Brooks, Jenny Johns, Emily S Wilson, Marjorie M A de Souza, Natasa Broit, Praphaporn Stewart, Daniel Shelley, Tracey McMahon, Steven M Ogbourne, Tam Hong Nguyen, Yi Chieh Lim, Alberto Pagani, Giovanni Appendino, Victoria A Gordon, Paul W Reddell, Glen M Boyle, Peter G Parsons
Original research: Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival (9 April, 2024)
Praveen K Bommareddy, Hiroaki Wakimoto, Robert L Martuza, Howard L Kaufman, Samuel D Rabkin, Dipongkor Saha

Position article and guidelines

Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease (18 April, 2024)
Jason J Luke, Diwakar Davar, Robert H Andtbacka, Nina Bhardwaj, Joshua D Brody, Jason Chesney, Robert Coffin, Thierry de Baere, Tanja D de Gruijl, Matthew Fury, Gregory Goldmacher, Kevin J Harrington, Howard Kaufman, Ciara M Kelly, Anuradha D Khilnani, Ke Liu, Sherene Loi, Georgina V Long, Ignacio Melero, Mark Middleton, Bart Neyns, David J Pinato, Rahul A Sheth, Stephen B Solomon, Philippe Szapary, Aurelien Marabelle
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy (10 April, 2024)
Steven T Chen, Yevgeniy R Semenov, Allireza Alloo, Daniel Q Bach, Allison Betof Warner, Amina Bougrine, Leeann Burton, Laura C Cappelli, Mariana Castells, Justine Cohen, Anna K Dewan, Riley Fadden, Lauren Guggina, Aparna Hegde, Victor Huang, Douglas B Johnson, Benjamin Kaffenberger, Daniela Kroshinsky, Shawn Kwatra, Bernice Kwong, Mario E Lacouture, Cecilia Larocca, Jonathan Leventhal, Alina Markova, Jon McDunn, Meghan J Mooradian, Jarushka Naidoo, Jennifer Choi, Vinod Nambudiri, Caroline A Nelson, Anisha B Patel, Julia Pimkina, Johnathan Rine, Krista M Rubin, Maxwell Sauder, Sheila Shaigany, Afreen Shariff, Ryan J Sullivan, Leyre Zubiri, Kerry L Reynolds, Nicole R LeBoeuf

Review

B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors (16 April, 2024)
Ronan Flippot, Marcus Teixeira, Macarena Rey-Cardenas, Lucia Carril-Ajuria, Larissa Rainho, Natacha Naoun, Jean-Mehdi Jouniaux, Lisa Boselli, Marie Naigeon, Francois-Xavier Danlos, Bernard Escudier, Jean-Yves Scoazec, Lydie Cassard, Laurence Albiges, Nathalie Chaput

Main menu

Table of contents

April 2024 - Volume 12 - 4

Basic tumor immunology

Case report

Commentary

Clinical/translational cancer immunotherapy

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Letter

Oncolytic and local immunotherapy

Position article and guidelines

Review

Correction

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

April 2024 - Volume 12 - 4

Basic tumor immunology

Case report

Commentary

Clinical/translational cancer immunotherapy

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Letter

Oncolytic and local immunotherapy

Position article and guidelines

Review

Correction